ABL Bio to Participate in World ADC San Diego
Presentation on the Safety and Efficacy of Bispecific Antibody ADCs
ABL Bio, a company specializing in bispecific antibodies, announced on October 21 that it will participate in the 16th World ADC San Diego 2025, which will be held in San Diego, California, USA, from November 3 to 6 (local time), where it will present its bispecific antibody ADC development strategy.
The World ADC series is the largest global event dedicated to ADCs. It brings together a diverse group of participants interested in ADCs to discuss development strategies and new technologies. In June, World ADC Asia, one of the World ADC series events, was held in Incheon. Following its participation in World ADC Asia, ABL Bio will also present on bispecific antibody ADCs at this World ADC San Diego. The presentation is scheduled for November 4.
The topic of ABL Bio's presentation is "Validation of Novel Target Combinations for Bispecific ADCs: Enhanced Tumor Selectivity and Reduced Off-Target Toxicity." Through this, the company plans to demonstrate the improved safety and efficacy of bispecific ADCs with dual target combinations compared to single-antibody ADCs.
Lee Sanghoon, CEO of ABL Bio, stated, "We are increasingly getting opportunities to introduce our bispecific antibody ADC development strategy on the global stage, which reflects the growing interest in bispecific ADCs. Currently, we are finalizing preparations for the entry of our bispecific antibody ADCs, ABL206 and ABL209, into Phase 1 clinical trials. Through rapid clinical development, we aim to secure leadership in the bispecific ADC market."
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- [Exclusive] K-Growth CEO Appointment Process Nears Completion... KDB Candidate Excluded
- The Unexpected Story of an American Man Who Won the Lottery 18 Times in 29 Years: "My Real Luck Is My Wife"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Last year, ABL Bio began full-scale development of next-generation ADCs, including bispecific antibody ADCs and dual payload ADCs, and is currently developing bispecific ADCs such as ABL206 and ABL209 at the preclinical stage. ABL Bio plans to submit Investigational New Drug (IND) applications for ABL206 and ABL209 to enter Phase 1 clinical trials in the United States at the end of this year and early next year, respectively. Subsequent clinical development following IND approval will be carried out by ABL Bio's independent U.S. subsidiary, Neok Bio.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
